A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.

开始日期2025-03-01

申办/合作机构

Hadassah University Hospital

NCT06097832

/ Recruiting临床1/2期

Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis

Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).

开始日期2024-06-05

申办/合作机构

Nexcella, Inc.

[+1]

NCT04720313

/ Active, not recruiting临床1期IIT

A Phase 1 Dose Escalation and Safety Study of NXC-201 (formerly HBI0101) CART in BCMA-Expressing Multiple Myeloma Patients

It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma and AL amyloidosis Patients

开始日期2021-01-01

申办/合作机构

Hadassah University Hospital

[+1]

100 项与 NXC-201 相关的临床结果

登录后查看更多信息

100 项与 NXC-201 相关的转化医学

登录后查看更多信息

100 项与 NXC-201 相关的专利（医药）

登录后查看更多信息

项与 NXC-201 相关的文献（医药）

2025-04-24·JOURNAL OF MEDICINAL CHEMISTRY

Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of Psoriasis

Article

作者: Cummings, Maxwell D. ; Albers, Michael ; Hoffmann, Thomas ; Goldberg, Steven D. ; Kleymann, Gerald ; Milligan, Cynthia ; Steeneck, Christoph ; Tanis, Virginia M. ; Venkatesan, Hariharan ; Fourie, Anne M. ; Sales, Zachary S. ; Schlüter, Thomas ; Schoetens, Freddy ; Spurlino, John ; Xue, Xiaohua ; Gege, Christian ; Kinzel, Olaf ; Scott, Brian ; Sepassi, Kia ; Edwards, James P. ; Coe, Kevin

The retinoic acid receptor-related orphan receptor gamma t (RORγt) is a nuclear transcription factor expressed in both innate and adaptive immune cells, driving Th17 cell differentiation and IL-17 production. The IL-23/IL-17 pathway is implicated in autoimmune and inflammatory diseases, and biologics that target IL-23/IL-17 signaling are efficacious in the treatment of psoriasis and psoriatic arthritis. RORγt, at the core of this pathway, represents an attractive opportunity for small-molecule intervention; however, combining high potency, nuclear receptor selectivity, and good physicochemical properties remains a challenge for RORγt inverse agonists. Recently, thiazole amides have been identified as potent RORγt inverse agonists; however, they often suffer from CYP450 autoinduction in the rat, precluding further development. Herein, we describe the discovery and development of potent and selective thiazole bisamide RORγt inverse agonists that avoid autoinduction in the rat. This effort culminated in the discovery of JNJ-61803534, which advanced into phase 1 clinical trials.

2024-08-13·Blood Advances

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma

Article

作者: Grisariu, Sigal ; Avni, Batia ; Shehadeh, Alaa ; Kenett, Ron S ; Bessig, Nomi ; Cohen, Cyrille J ; Zimran, Eran ; Avivi, Irit ; Elias, Shlomo ; Cohen, Yael ; Dubnikov Sharon, Tatyana ; Asherie, Nathalie ; Alexander-Shani, Rivka ; Lebel, Eyal ; Stepensky, Polina ; Assayag, Miri ; Pick, Marjorie ; Vainstein, Vladimir ; Zelmanovich, Veronica ; Gatt, Moshe E ; Roziner, Ilan ; Kfir-Erenfeld, Shlomit ; Ishtay, Aseel

Abstract:

HBI0101 is an academic chimeric antigen receptor T-cell (CART)–targeted to B-cell maturation antigen (BCMA) for the treatment of relapsed and refractory multiple myeloma (R/RMM) and light chain amyloidosis. Herein, we present the phase 1b/2 results of 50 heavily pretreated patients with R/RMM dosed with 800 × 106 CART cells. Inclusion criteria were relatively permissive (i.e., performance status and baseline organ function) and consequently, approximately half of the enrolled patients would have been ineligible for pivotal clinical trials. The median time elapsed from patient enrollment until CART delivery was 25 days (range, 14-65). HBI0101-related toxicities included grade 1 to 3 cytokine release syndrome, grade 3 to 4 hematologic toxicities, and grade 1 to 2 immune effector cell–associated neurotoxicity syndrome. Responses were achieved in 90% of the patients, 56% achieved stringent and complete response, and 70% reached a minimal residual disease negativity. Within a median follow-up of 12.3 months, the median progression-free survival (PFS) was 11.0 months (95% confidence interval [CI], 6.2-14.6), and the overall survival was not reached (95% CI, 13.3 to not reached). Multivariable analysis on patient/disease and CART-related characteristics revealed that high-risk cytogenetic, extramedullary disease, and increased number of effector-memory T cells in CART products were independently associated with inferior PFS. In conclusion, comprehensive analyses of the parameters affecting the response to CART therapy are essential for improving patients’ outcome. This trial was registered at www.ClinicalTrials.gov as #NCT04720313.

2022-12-01·Clinical cancer research : an official journal of the American Association for Cancer Research

Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Article

作者: Shaulov, Adir ; Avni, Batia ; Pick, Marjorie ; Assayag, Miri ; Gatt, Moshe E. ; Cohen, Cyrille J. ; Cohen, Yael C. ; Asherie, Nathalie ; Lebel, Eyal ; Avivi, Irit ; Stepensky, Polina ; Zimran, Eran ; Sharon, Tatyana Dubnikov ; Grisariu, Sigal ; Kfir-Erenfeld, Shlomit

Abstract:

Purpose::

AL amyloidosis (AL) treatments are generally based on those employed for multiple myeloma. Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T (CART)-cell therapy, already approved for multiple myeloma, might be too toxic for patients with AL.

Experimental Design::

Here we describe the ex vivo applicability of a novel in-house, academic anti-BCMA CAR construct on AL primary cells, as well as the safety and efficacy in 4 patients with relapsed/refractory (RR) primary AL, treated in a phase I clinical trial (NCT04720313).

Results::

Three had MAYO stage IIIa cardiac involvement at enrollment. The treatment proved relatively safe, with a short and manageable grade 3 cytokine release syndrome evident in 2 patients and no neurotoxicity in any. Cardiac decompensations, observed in 2 patients, were also short and manageable. The overall hematologic response and complete response rates were observed in all patients with an organ response evident in all four. Within a median follow-up period of 5.2 (2.5–9.5) months, all 4 patients maintained their responses.

Conclusions::

BCMA-CART cells provide a first proof-of-concept that this therapy is safe enough and highly efficacious for the treatment of patients with advanced, RR AL.

141

项与 NXC-201 相关的新闻（医药）

2025-07-11

·GlobeNewswire-Health Care

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned – LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced a class-leading safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any grade in low-volume disease to-date, laying a foundation for potential future indication expansion. “We are singularly focused on completing NEXICART-2 for BLA submission, where we are accelerating progress. Separately and subsequently, for potential future expansion directions, we believe NXC-201 will be able to address a range of immune-mediated and other serious diseases,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Our near-term efforts are laser- focused on our path to NEXICART-2 BLA submission for FDA approval.” NEXICART-2 interim results, including safety results, were presented at the American Society for Clinical Oncology (ASCO 2025) by Heather Landau, MD of Memorial Sloan Kettering Cancer Center can be accessed on the Company’s website under publications (ASCO Post article and video, MSKCC article, Cleveland Clinic article). A webcast of the Company’s Key Opinion Leader (KOL) event to discuss the NXC-201 ASCO 2025 interim results, including safety results, can be accessed here. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. Interim results were presented at ASCO 2025 in an oral presentation by Heather Landau, M.D. of Memorial Sloan Kettering Cancer Center. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com. About AL AmyloidosisAL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that circulate in the blood, then build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread organ damage, including heart and renal failure, leading to high mortality rates. The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 33,277 patients in 2024. The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research. Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. ContactsMike MoyerLifeSci Advisorsmmoyer@lifesciadvisors.com Company Contactirteam@immixbio.com

细胞疗法临床研究ASCO会议孤儿药临床结果

2025-06-06

·GlobeNewswire-Health Care

Immix Biopharma Attends FDA CEO Forum in Washington DC

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it was selected by FDA, and attended, the FDA CEO forum led by FDA Commissioner Marty A. Makary, M.D., M.P.H. and team at FDA headquarters in Silver Spring, MD, on June 5, 2025. Per FDA, the purpose of the meeting is to gather direct input from biotechnology and pharmaceutical leaders on how the FDA can modernize its regulatory framework to better support innovation and patient access to safe and effective therapies. FDA Commissioner Marty A. Makary, M.D., M.P.H. stated, “These CEO Forums are a chance for the FDA to listen and gather feedback from those at the front lines of discovery. We are committed to strengthening a regulatory environment that enables breakthroughs to reach patients faster, while upholding the highest standards of safety and scientific integrity.“ “We share FDA’s vision for an efficient, thoughtful regulatory framework to accelerate patient access to safe and effective therapies. Discussing this topic with FDA Commissioner Dr. Makary and team yesterday offered an unprecedented opportunity,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “As we progress, we were thrilled to be selected alongside other leaders of the global pharmaceutical industry. We are grateful that FDA facilitated this important, collaborative discussion.” About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. Interim results were presented at ASCO 2025 in an oral presentation by Heather Landau, M.D. of Memorial Sloan Kettering Cancer Center. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com. Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. ContactsMike MoyerLifeSci Advisorsmmoyer@lifesciadvisors.com Company Contactirteam@immixbio.com

孤儿药细胞疗法

2025-05-26

·GlobeNewswire-Health Care

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – May 23, 2025 -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone adds 10 sites since the Company’s most recent update. The company anticipates completing NEXICART-2 clinical trial ahead of schedule. “Based on robust enrollment and demand, we are proud to expand our NEXICART-2 clinical trial footprint to a significant number of national AL Amyloidosis centers,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Working with these world-class sites, we believe we are well positioned to complete NEXICART-2 on time or even ahead of schedule.” Phase 1/2 interim readout data from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) being held in Chicago, Illinois, May 30 – June 3, 2025, presented by lead investigator Heather Landau, M.D., Director of Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York. NEXICART-2 (NCT06097832) is an ongoing single-arm multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. NEXICART-2 is expected to enroll 40 patients with preserved heart function (excluding patients with pre-existing heart failure) who have not been exposed to prior BCMA-targeted therapy. The primary endpoint of the Phase 1 portion is safety. The primary endpoint of the Phase 2 portion is efficacy. NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a “digital filter” that filters out non-specific activation. Initial data from ex-U.S. study NEXICART-1 has demonstrated high complete response rates in relapsed/refractory AL Amyloidosis. U.S. Phase 1/2 study NEXICART-2 is ongoing. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA. AL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that circulate in the blood, then build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread organ damage, including heart and renal failure, leading to high mortality rates. The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 33,277 patients in 2024. The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. multi-center study NEXICART-2 (NCT06097832). NXC-201 has demonstrated no neurotoxicity in AL Amyloidosis, supporting expansion into other serious diseases. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. The content above comes from the network. if any infringement, please contact us to modify.

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

孤儿药临床研究细胞疗法免疫疗法ASCO会议

100 项与 NXC-201 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫球蛋白轻链淀粉样变性	临床2期	美国	Nexcella, Inc.	2024-06-05
多发性骨髓瘤	临床2期	美国	Immix Biopharma, Inc.	-
BCMA阳性多发性骨髓瘤	临床1期	以色列	Nexcella, Inc.	2021-01-01
难治性多发性骨髓瘤	临床1期	以色列	Nexcella, Inc.	2021-01-01
自身免疫性疾病	临床前	以色列	Nexcella, Inc.	2024-03-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06097832 (NEXICART-2, ASCO2025)	临床1/2期	免疫球蛋白轻链淀粉样变性 BCMA	40	NXC-201	觸網醖廠願遞顧製憲選(構夢簾網餘醖網鏇遞鬱) = CRS was observed in 5 pts (grade 1 (N=4), grade 2 (N=1)); onset day 1 (N=3) or 3 (N=2), lasting <24 hours following 1 dose of tocilizumab in all pts 醖鹽廠醖範鏇壓醖範鹽 (獵鏇廠構願鹹淵齋簾築 ) 更多	积极	2025-05-30
NCT06097832 (NEXICART-2, NEWS) 人工标引	临床1/2期	免疫球蛋白轻链淀粉样变性	4	NXC-201 150 million CAR+T cells	觸選簾構鹽齋觸鹽窪獵(顧衊選繭願鹹獵齋構簾) = 鬱觸糧餘獵鬱壓構憲鬱選廠遞憲憲積衊憲艱構 (艱膚窪製廠壓簾觸憲窪 ) 更多	积极	2024-12-19
NCT06097832 (NEXICART-2, NEWS) 人工标引	临床1/2期	免疫球蛋白轻链淀粉样变性	4	NXC-201 450 million CAR+T cells	築鑰鹽鑰鬱憲觸醖鬱壓(糧鏇構鑰鏇遞艱齋選齋) = 遞衊廠蓋窪鏇膚蓋餘憲獵簾壓夢艱齋糧繭醖齋 (鑰網遞鬱築顧鏇選糧構 ) 更多	积极	2024-12-19
NCT04720313 (HBI0101, Pubmed)	临床1/2期	复发性多发性骨髓瘤 high-risk cytogenetic \| extramedullary disease	50	HBI0101 (BCMA CART) therapy	壓遞築艱遞簾衊鏇鹹壓(鬱廠廠構願積願範糧鑰) = grade 1 to 3 cytokine release syndrome 獵窪簾獵鏇獵簾鑰鑰蓋 (願顧憲簾蓋壓鏇築襯範 ) 更多	积极	2024-08-13
NCT04720313 (NEXICART-1, Biospace) 人工标引	临床1期	免疫球蛋白轻链淀粉样变性	13	NXC-201	衊齋獵鹹衊簾鏇襯壓觸(壓築鑰鏇簾淵糧範淵顧) = 鏇鹹糧壓獵觸願網製範築鹹壓範襯鬱獵顧繭廠 (鏇築繭鹽衊觸簾壓選繭 ) 更多	积极	2024-05-10
NCT04720313 (NEXICART-1, Biospace) 人工标引	临床1期	免疫球蛋白轻链淀粉样变性	13	NXC-201 (pts not exposed to prior BCMA-targeted bispecific)	衊齋獵鹹衊簾鏇襯壓觸(壓築鑰鏇簾淵糧範淵顧) = 製膚鬱壓餘艱築淵廠鹽築鹹壓範襯鬱獵顧繭廠 (鏇築繭鹽衊觸簾壓選繭 ) 更多	积极	2024-05-10
ASH2023	临床1/2期	复发性多发性骨髓瘤	51	HBI0101	廠簾願積夢願膚鏇窪顧(廠遞遞獵鹽選糧餘積簾) = 構淵衊構餘獵鏇衊窪鬱鹽願襯糧築繭鏇製遞壓 (簾選膚鹹製選蓋餘製憲 ) 更多	-	2023-12-11
NCT04720313 (ASH2023)	临床1/2期	免疫球蛋白轻链淀粉样变性	9	HBI0101 therapy	蓋鬱糧餘醖獵衊膚網繭(獵膚鹹遞構夢蓋蓋鹽鑰) = 壓衊憲夢衊網憲鹽鑰壓夢襯醖繭鹽壓壓襯窪襯 (製衊淵築遞糧積繭網願 ) 更多	积极	2023-12-10
NCT04720313 (NEXICART-1, Corporate Publications) 人工标引	临床1/2期	免疫球蛋白轻链淀粉样变性	9	NXC-201 (heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis)	餘鏇選艱壓觸齋遞衊鏇(糧範蓋積齋鑰製簾襯觸) = 窪艱艱鏇鏇積觸壓網餘齋衊鑰願觸製齋鹽築築 (廠範衊觸淵襯艱糧衊夢 ) 更多	积极	2023-10-03
NCT04720313 (NEXICART-1, Corporate Publications) 人工标引	临床1/2期	免疫球蛋白轻链淀粉样变性	9	NXC-201 (t(11;14) relapsed/refractory AL Amyloidosis)	餘鏇選艱壓觸齋遞衊鏇(糧範蓋積齋鑰製簾襯觸) = 觸鏇顧鏇壓齋膚廠窪壓齋衊鑰願觸製齋鹽築築 (廠範衊觸淵襯艱糧衊夢 ) 更多	积极	2023-10-03
NCT04720313 (IMS2023)	临床1期	复发性多发性骨髓瘤	50	HBI0101	鑰淵淵獵顧壓願壓窪製(遞繭醖淵鑰壓醖窪蓋構) = 壓網繭醖淵鑰鬱淵製鏇壓繭糧糧積顧餘淵艱淵 (鑰齋膚構簾窪衊醖願獵 ) 更多	-	2023-09-26
NCT04720313 (GlobeNewswire) 人工标引	临床1期	多发性骨髓瘤	42	NXC-201	網鑰獵積積襯齋衊範糧(觸顧艱窪選夢繭蓋夢醖) = 觸壓鬱夢艱廠鬱鬱範構選衊鑰網構觸遞願鹹鬱 (鹹繭鹹醖網鹹餘顧顧鹽 ) 更多	积极	2023-02-09
NCT04720313 (GlobeNewswire) 人工标引	临床1期	多发性骨髓瘤	42	NXC-201 (800 million CAR+T cells)	網鑰獵積積襯齋衊範糧(觸顧艱窪選夢繭蓋夢醖) = 淵艱廠鏇繭糧築構餘膚選衊鑰網構觸遞願鹹鬱 (鹹繭鹹醖網鹹餘顧顧鹽 ) 更多	积极	2023-02-09
NCT04720313 (Pubmed) 人工标引	临床1期	多发性骨髓瘤	20	HBI0101	選鑰醖衊膚製鏇壓願淵(蓋膚艱醖衊醖範醖憲齋) = 壓蓋構襯獵醖醖築鏇觸觸鬱醖醖觸製繭衊鬱選 (繭襯願夢艱鹹獵顧淵夢 ) 更多	积极	2022-10-06